238 related articles for article (PubMed ID: 38023176)
1. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Rugambwa TK; Abdihamid O; Zhang X; Peng Y; Cai C; Shen H; Zeng S; Qiu W
Front Oncol; 2023; 13():1181248. PubMed ID: 38023176
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
3. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
Zheng L; Xiong A; Wang S; Xu J; Shen Y; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
Front Immunol; 2023; 14():1094378. PubMed ID: 36776882
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: a systematic review and meta-analysis.
Matsas S; Aguiar PN; Del Giglio A
J Gastrointest Oncol; 2024 Feb; 15(1):33-51. PubMed ID: 38482212
[TBL] [Abstract][Full Text] [Related]
5. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.
Dharmapuri S; Özbek U; Jethra H; Jun T; Marron TU; Saeed A; Huang YH; Muzaffar M; Pinter M; Balcar L; Fulgenzi C; Amara S; Weinmann A; Personeni N; Scheiner B; Pressiani T; Navaid M; Bengsch B; Paul S; Khan U; Bettinger D; Nishida N; Mohamed YI; Vogel A; Gampa A; Korolewicz J; Cammarota A; Kaseb A; Galle PR; Pillai A; Wang YH; Cortellini A; Kudo M; D'Alessio A; Rimassa L; Pinato DJ; Ang C
World J Gastrointest Oncol; 2023 Nov; 15(11):1900-1912. PubMed ID: 38077640
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen X; Meng F; Jiang R
Front Oncol; 2021; 11():746976. PubMed ID: 34900692
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis.
Lu HR; Zhu PF; Deng YY; Chen ZL; Yang L
Clin Transl Oncol; 2024 May; 26(5):1106-1116. PubMed ID: 37682501
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.
Dharmapuri S; Özbek U; Lin JY; Sung M; Schwartz M; Branch AD; Ang C
Cancer Med; 2020 Jul; 9(14):4962-4970. PubMed ID: 32419290
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
Leng J; Wu F; Zhang L
Front Oncol; 2022; 12():734948. PubMed ID: 35651788
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Zhang S; Qiu C; Yu H; Xu Y; Xu X
Front Oncol; 2023; 13():1070019. PubMed ID: 37143942
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis.
Zhou K; Cao J; Lin H; Liang L; Shen Z; Wang L; Peng Z; Mei J
Front Oncol; 2022; 12():962173. PubMed ID: 36059629
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
Tan Q; Liu S; Liang C; Han X; Shi Y
Thorac Cancer; 2018 Oct; 9(10):1220-1230. PubMed ID: 30151899
[TBL] [Abstract][Full Text] [Related]
13. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of preoperative lymphocyte-related systemic inflammatory biomarkers in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: a systematic review and meta-analysis.
Shao Y; Li W; Wang D; Wu B
World J Surg Oncol; 2020 Oct; 18(1):273. PubMed ID: 33097052
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.
Platini H; Ferdinand E; Kohar K; Prayogo SA; Amirah S; Komariah M; Maulana S
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013536
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Prognostic Markers {CEA, Ca19.9, Neutrophil To Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)} With Progression Free Survival (PFS) in Advanced/Metastatic Gallbladder Carcinoma.
Naik MD; Kataria SP; Kumar G; Singh R
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443542
[TBL] [Abstract][Full Text] [Related]
17. Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer.
Lu X; Wan J; Shi H
Oncol Lett; 2022 Aug; 24(2):266. PubMed ID: 35782904
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
19. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer.
Hirahara T; Arigami T; Yanagita S; Matsushita D; Uchikado Y; Kita Y; Mori S; Sasaki K; Omoto I; Kurahara H; Maemura K; Okubo K; Uenosono Y; Ishigami S; Natsugoe S
BMC Cancer; 2019 Jul; 19(1):672. PubMed ID: 31286873
[TBL] [Abstract][Full Text] [Related]
20. Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review.
Guo Y; Xiang D; Wan J; Yang L; Zheng C
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
